NASDAQ:RSLS ReShape Lifesciences Q1 2025 Earnings Report $2.49 +0.05 (+2.05%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.46 -0.03 (-1.16%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History ReShape Lifesciences EPS ResultsActual EPS$18.98Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AReShape Lifesciences Revenue ResultsActual Revenue$1.11 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AReShape Lifesciences Announcement DetailsQuarterQ1 2025Date5/20/2025TimeAfter Market ClosesConference Call DateTuesday, May 20, 2025Conference Call Time4:00PM ETUpcoming EarningsReShape Lifesciences' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Tuesday, August 19, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ReShape Lifesciences Earnings HeadlinesReShape Lifesciences Holds Special Stockholder MeetingJuly 25, 2025 | tipranks.comReShape Lifesciences® Announces Partial Adjournment of Special Meeting of StockholdersJuly 24, 2025 | globenewswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon SummitJuly 22, 2025 | globenewswire.comReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025July 21, 2025 | globenewswire.comReShape Lifesciences provides $200,000 loan to Vyome Therapeutics under merger terms - Investing.comJuly 5, 2025 | investing.comSee More ReShape Lifesciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ReShape Lifesciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ReShape Lifesciences and other key companies, straight to your email. Email Address About ReShape LifesciencesReShape Lifesciences (NASDAQ:RSLS) provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.View ReShape Lifesciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? Upcoming Earnings Palantir Technologies (8/4/2025)Vertex Pharmaceuticals (8/4/2025)Axon Enterprise (8/4/2025)MercadoLibre (8/4/2025)Williams Companies (8/4/2025)Simon Property Group (8/4/2025)Advanced Micro Devices (8/5/2025)Marriott International (8/5/2025)Amgen (8/5/2025)Itau Unibanco (8/5/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.